Firy Inc. vs Novavax Inc — how do they compare? Firy Inc. trades at $11.73 (market cap $199.80M), while Novavax Inc trades at $11.11 (market cap $1.82B). The key difference: Novavax Inc is far larger — about 9.1× Firy Inc.'s market cap, and Firy Inc. is trading nearer its 52-week high, Novavax Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Firy Inc. for 13 Days and Novavax Inc for 59 Days on average.
| FIRY | NVAX | |
|---|---|---|
Market Cap | $199.80M | $1.82B |
Volume | 92,993 | 6,198,505 |
Sector | Technology | Health |
52-Week High | $13.10 | $12.56 |
52-Week Low | $2.28 | $6.22 |
Typical Hold Time | 13 Days | 59 Days |
Enterprise Value | $168.40M | $1.39B |
Signals from Pluang's Aura AI — not financial advice
FIRY (formerly Skillz Inc.) trades at $11.85, down 5.05% today, showing continued volatility amid its transition to a holding company structure. The stock maintains a bullish technical signal despite negative profitability metrics, with revenue stabilizing around $100M annually but net losses persisting. Recent developments include a $719M legal victory against Papaya Gaming and board additions, though cash burn remains elevated at -$86M in 2025.
The outlook remains speculative with significant execution risk. While the legal win provides potential upside, persistent losses and cash burn challenge near-term viability. Analyst consensus is cautious with 60% hold ratings, reflecting uncertainty around the company's ability to monetize assets and achieve profitability.
Novavax (NVAX) trades at $11.22, down 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support (74% buy ratings). The company shows mixed fundamentals with a positive P/E of 3.14 and EV/EBITDA of 1.72, but negative net income margin of -59.87% and negative shareholder equity. Recent developments include regulatory approvals for its updated COVID-19 vaccine and strategic pivot toward Matrix-M adjuvant licensing partnerships.
The outlook remains speculative with significant execution risks in the transition from COVID vaccine dependency to partnership-driven model. While valuation metrics appear attractive and technical momentum is positive, persistent negative cash flows and competitive pressures in the biotech sector warrant caution. The stock presents high-risk, high-reward potential for investors comfortable with biotech volatility.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
Firy Inc. operates a mobile gaming platform in the United States, Israel, China, Malta, Hong Kong, Cyprus, and other international markets. The company operates through two segments: Skillz and RZR. Its Skillz platform enables game developers to monetize their content by integrating real-money tournaments, virtual prizes, and social competition features directly into multiplayer games.
Read more on FIRY →Novavax, Inc. is a clinical stage biotechnology company. The Company creates novel vaccines to address a broad range of infectious diseases worldwide using proprietary virus-like particle (VLP) technology.
Read more on NVAX →